» Articles » PMID: 34351358

Applying a Life Course Biological Age Framework to Improving the Care of Individuals With Adult Cancers: Review and Research Recommendations

Overview
Journal JAMA Oncol
Specialty Oncology
Date 2021 Aug 5
PMID 34351358
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: The practice of oncology will increasingly involve the care of a growing population of individuals with midlife and late-life cancers. Managing cancer in these individuals is complex, based on differences in biological age at diagnosis. Biological age is a measure of accumulated life course damage to biological systems, loss of reserve, and vulnerability to functional deterioration and death. Biological age is important because it affects the ability to manage the rigors of cancer therapy, survivors' function, and cancer progression. However, biological age is not always clinically apparent. This review presents a conceptual framework of life course biological aging, summarizes candidate measures, and describes a research agenda to facilitate clinical translation to oncology practice.

Observations: Midlife and late-life cancers are chronic diseases that may arise from cumulative patterns of biological aging occurring over the life course. Before diagnosis, each new patient was on a distinct course of biological aging related to past exposures, life experiences, genetics, and noncancer chronic disease. Cancer and its treatments may also be associated with biological aging. Several measures of biological age, including p16INK4a, epigenetic age, telomere length, and inflammatory and body composition markers, have been used in oncology research. One or more of these measures may be useful in cancer care, either alone or in combination with clinical history and geriatric assessments. However, further research will be needed before biological age assessment can be recommended in routine practice, including determination of situations in which knowledge about biological age would change treatment, ascertaining whether treatment effects on biological aging are short-lived or persistent, and testing interventions to modify biological age, decrease treatment toxic effects, and maintain functional abilities.

Conclusions And Relevance: Understanding differences in biological aging could ultimately allow clinicians to better personalize treatment and supportive care, develop tailored survivorship care plans, and prescribe preventive or ameliorative therapies and behaviors informed by aging mechanisms.

Citing Articles

Epigenetic Landscapes of Aging in Breast Cancer Survivors: Unraveling the Impact of Therapeutic Interventions-A Scoping Review.

Nikita N, Sun Z, Sharma S, Shaver A, Seewaldt V, Lu-Yao G Cancers (Basel). 2025; 17(5).

PMID: 40075712 PMC: 11899678. DOI: 10.3390/cancers17050866.


Insights to aging prediction with AI based epigenetic clocks.

Levy J, Diallo A, Saldias Montivero M, Gabbita S, Salas L, Christensen B Epigenomics. 2024; 17(1):49-57.

PMID: 39584810 PMC: 11703013. DOI: 10.1080/17501911.2024.2432854.


Physical Activity and Epigenetic Aging in Breast Cancer Treatment.

Moulton C, Grazioli E, Ibanez-Cabellos J, Murri A, Cerulli C, Silvestri M Int J Mol Sci. 2024; 25(16).

PMID: 39201283 PMC: 11355047. DOI: 10.3390/ijms25168596.


Gerotherapeutics: aging mechanism-based pharmaceutical and behavioral interventions to reduce cancer racial and ethnic disparities.

Mandelblatt J, Antoni M, Bethea T, Cole S, Hudson B, Penedo F J Natl Cancer Inst. 2024; 117(3):406-422.

PMID: 39196709 PMC: 11884862. DOI: 10.1093/jnci/djae211.


Systemic DNA Damage and Repair Activity Vary by Race in Breast Cancer Survivors.

Divekar S, Kritzer R, Shu H, Thakkar K, Hicks J, Mills M Cancers (Basel). 2024; 16(10).

PMID: 38791886 PMC: 11119753. DOI: 10.3390/cancers16101807.


References
1.
Anisimov V . Metformin for cancer and aging prevention: is it a time to make the long story short?. Oncotarget. 2015; 6(37):39398-407. PMC: 4741834. DOI: 10.18632/oncotarget.6347. View

2.
Garatachea N, Pareja-Galeano H, Sanchis-Gomar F, Santos-Lozano A, Fiuza-Luces C, Moran M . Exercise attenuates the major hallmarks of aging. Rejuvenation Res. 2014; 18(1):57-89. PMC: 4340807. DOI: 10.1089/rej.2014.1623. View

3.
Rentscher K, Carroll J, Mitchell C . Psychosocial Stressors and Telomere Length: A Current Review of the Science. Annu Rev Public Health. 2020; 41:223-245. DOI: 10.1146/annurev-publhealth-040119-094239. View

4.
Moskalev A, Chernyagina E, Kudryavtseva A, Shaposhnikov M . Geroprotectors: A Unified Concept and Screening Approaches. Aging Dis. 2017; 8(3):354-363. PMC: 5440114. DOI: 10.14336/AD.2016.1022. View

5.
Song N, Li Z, Qin N, Howell C, Wilson C, Easton J . Shortened Leukocyte Telomere Length Associates with an Increased Prevalence of Chronic Health Conditions among Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort. Clin Cancer Res. 2020; 26(10):2362-2371. PMC: 7231652. DOI: 10.1158/1078-0432.CCR-19-2503. View